Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with ...

Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and ...

Among Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis, treatment with the combination of pelabresib and ...

Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and ...

Investing.com -- Beam Therapeutics Inc. (NASDAQ:BEAM) stock surged 12% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy ...

The CAR-T treatment GLPG5101 received the FDA's RMAT designation by showing promising efficacy with rapid delivery and low toxicity in mantle cell lymphoma.

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and ...

Continuing his interview about these results, CEPHEUS lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, highlights the minimal residual disease negativity findings.

Q2 2025 Earnings Call Transcript August 12, 2025 ADC Therapeutics S.A. misses on earnings expectations. Reported EPS is $-0.5 ...

Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

WILMINGTON, Del., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for second ...